Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters
Y Ma, S Xin, M Huang, Y Yang, C Zhu, H Zhao… - The …, 2017 - nature.com
Skin rash, diarrhea and hepatotoxicity are the most common toxicities of Gefitinib, an
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. The present study …
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. The present study …
Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters
Y Ma, S Xin, M Huang, Y Yang… - The …, 2017 - pubmed.ncbi.nlm.nih.gov
Skin rash, diarrhea and hepatotoxicity are the most common toxicities of Gefitinib, an
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. The present study …
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. The present study …
Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters.
Y Ma, S Xin, M Huang, Y Yang, C Zhu… - The …, 2017 - go.gale.com
Skin rash, diarrhea and hepatotoxicity are the most common toxicities of Gefitinib, an
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. The present study …
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. The present study …
Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters.
Y Ma, S Xin, M Huang, Y Yang, C Zhu… - The …, 2016 - europepmc.org
Skin rash, diarrhea and hepatotoxicity are the most common toxicities of Gefitinib, an
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. The present study …
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. The present study …
[引用][C] Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters
Y Ma, S Xin, M Huang, Y Yang, C Zhu, H Zhao… - The …, 2016 - cir.nii.ac.jp
Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a
pharmacogenomic study of metabolic enzymes and transporters | CiNii Research CiNii 国立 …
pharmacogenomic study of metabolic enzymes and transporters | CiNii Research CiNii 国立 …
[PDF][PDF] Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters
Y Ma, S Xin, M Huang, Y Yang, C Zhu… - The …, 2016 - researchgate.net
Lung cancer is the leading cause of death due to cancer throughout the world. Non-small
cell lung cancer (NSCLC) is the most common type of lung cancer. Gefitinib (IRESSA; …
cell lung cancer (NSCLC) is the most common type of lung cancer. Gefitinib (IRESSA; …
[PDF][PDF] Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters
Y Ma, S Xin, M Huang, Y Yang, C Zhu… - The …, 2016 - researchgate.net
Lung cancer is the leading cause of death due to cancer throughout the world. Non-small
cell lung cancer (NSCLC) is the most common type of lung cancer. Gefitinib (IRESSA; …
cell lung cancer (NSCLC) is the most common type of lung cancer. Gefitinib (IRESSA; …
Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters
Y Ma, S Xin, M Huang, Y Yang, C Zhu… - The …, 2017 - go.gale.com
Skin rash, diarrhea and hepatotoxicity are the most common toxicities of Gefitinib, an
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. The present study …
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. The present study …